Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors
Stocks in this Quantisnow insightHealth Care
Historical context for AGEN
Across the 8 sessions after earlier AGEN headlines, the stock closed higher 4 times and lower 4 times, with a median move of 3.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | AGEN | SPY |
|---|---|---|---|
| Jan 21, 2026 | Agenus to Host First 2026 Stakeholder Webcast | +0.9% | +1.2% |
| Jan 15, 2026 | Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.and 1 other headline that session | -21.4% | +0.3% |
| Jan 12, 2026 | France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas | +8.7% | +0.2% |
| Dec 23, 2025 | Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC | -5.7% | +0.5% |
| Nov 20, 2025 | Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL | +2.1% | -1.5% |
| Nov 18, 2025 | Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC | -2.1% | -0.8% |
Keep researching AGEN
Quantisnow market dataNASDAQ
AGEN
Agenus Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2000
Get push alerts for AGEN
Full AGEN profile on Quantisnow Follow AGEN and get a push notification the moment its next story breaks.